Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Promising Results Reported in Early-Phase Gene Therapy Trials for Two Types of Inherited Blindness
Gene therapy trials for hereditary blindness show significant improvement in night vision for patients with Leber congenital amaurosis 1 (LCA1) and RLBP-1 associated retinal dystrophy, with plans for future Phase III trials.
Welshare Health Introduces AI-Driven App to Inaugurate the Future of Patient-Driven
Welshare Health, a DeSci leader, is developing a decentralized app empowering individuals to contribute to AI-driven medical research, built on Base, enabling patients to control their health data and personalize contributions to studies. The app aims to revolutionize medical research and healthcare delivery.
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
The article discusses the importance of SSR (Server-Side Rendering) in modern web development for improving performance and SEO.
Dupixent approved in China as the first-ever biologic medicine for patients ...
Dupixent approved in China as the first biologic for COPD, following EU approval. Based on phase 3 studies, Dupixent significantly reduced exacerbations, improved lung function, and quality of life. COPD is a priority in China's Healthy China 2030 plan. Dupixent is now approved in four indications in China.
Dupixent approved in China as the first-ever biologic medicine for patients
Dupixent approved in China for COPD, reducing exacerbations, improving lung function, and enhancing quality of life in phase 3 studies.
Cardurion Pharmaceuticals Appoints Ron Renaud to Board of Directors
Cardurion Pharmaceuticals appoints Ron Renaud to its Board of Directors, leveraging his 25+ years of biotech experience to advance cardiovascular disease therapeutics.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
The drug and biotech sector has outperformed the broader market, driven by new drug launches, pipeline successes, and increased M&A activity. Eli Lilly's obesity drugs have been particularly successful. Despite headwinds like pipeline setbacks and economic uncertainty, the sector has seen a surge in investments. Five large drugmakers—Pfizer, Eli Lilly, AstraZeneca, Bayer, and Sanofi—are recommended for portfolio growth, with strong financials and robust pipelines.
Billion-Dollar AI Deals Powering Antibody Design, Biologics, and Next-Gen Therapies
AI-powered collaborations drive billion-dollar deals, accelerating antibody design, biopharmaceuticals, and next-gen biologics development.
Sarclisa granted FDA approval to treat newly diagnosed multiple myeloma
Sanofi's Sarclisa approved by FDA as first-line treatment for NDMM, in combination with VRd for non-transplant eligible patients. Supported by IMROZ trial results showing 40% reduced risk of disease progression or death. Median PFS not reached at 59.7 months with Sarclisa/VRd vs. 54.3 months with VRd.
© Copyright 2025. All Rights Reserved by MedPath